nach oben

Erschienen in:

16.08.2015 | Original Article

Targeting polyamine biosynthetic pathway through RNAi causes the abrogation of MCF 7 breast cancer cell line

Erschienen in: Tumor Biology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The diamine putrescine and polyamines, spermidine (triamine) and spermine (tetraamine) are small organic polycations that play an indispensable role in key cellular processes such as the regulation of growth, differentiation, and macromolecular functions. Elevated levels of polyamines (PAs) have been shown to be one of the major factors involved in carcinogenesis. In this study, specific silencing of the expression of three genes of PA biosynthesis pathway, ornithine decarboxylase (ODC), S-adenosylmethionine decarboxylase (SAMDC), and spermidine synthase (SPDSYN) was achieved using RNA interference in MCF 7 breast cancer cell line. For optimizing the effective small interfering nucleic acid (siNA), three variants of ODC siNA [siRNA, locked nucleic acid (LNA)-modified siRNA, and siHybrid (RNA and DNA hybrid)] were used and a dose- and time-dependent study was conducted. The PA biosynthetic genes were targeted individually and in combination. RNAi-mediated reduction in the expression of PA biosynthesis genes resulted in distorted cell morphology, reduced cancer cell viability, and migration characteristic. The most promising results were observed with the combined treatment of siSPDSYN and siODC with 83 % cell growth inhibition. On analyzing the messenger RNA (mRNA) expression profile of the cell cycle and apoptosis-related genes, it was observed that RNAi against PA biosynthetic genes downregulated the expression of CDK8, CCNE2, CCNH, CCNT1, CCNT2, CCNF, PCNA, CCND1, and CDK2, and upregulated the expression of E2F4, BAX, FAS, TP53, CDKN1A, BAK1, CDKN1B, ATM, GRANB, and ATR genes when compared with control-transfected cells. These results suggest that the targeting polyamine biosynthesis through RNAi approach could be a promising strategy for breast cancer therapy and might be extended for therapy of other cancers.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed

Speirs V. Perspective: not just for women. Nature. 2012;485:S66.CrossRefPubMed

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.CrossRefPubMed

Bachrach U. The early history of polyamine research. Plant Physiol Biochem. 2010;48:490–5.CrossRefPubMed

Pegg AE. Mammalian polyamine metabolism and function. IUBMB Life. 2009;61:880–94.CrossRefPubMedPubMedCentral

MV Rajam. Polyamines, in: M.N.V. Prasad (Ed.), Plant ecophysiology, John Wiley & Sons,Inc., 1997, pp. 343–374.

Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci. 2001;58:244–58.CrossRefPubMed

Rajam MV, Kumaria R, Waie B, Sharma R. Genetic manipulation of polyamine metabolism. In: Singh RP, Jaiwal PK, editors. Plant genetic engineering. USA: Sci. Tech. Publishing LLC; 2003. p. 179–98.

Gerner EW, Meyskens Jr FL. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004;4:781–92.CrossRefPubMed

10.

Andersson G, Heby O. Polyamine and nucleic acid concentrations in Ehrlich ascites carcinoma cells and liver of tumor-bearing mice at various stages of tumor growth. J Natl Cancer Inst. 1972;48:165–72.PubMed

11.

Russell D, Snyder SH. Amine synthesis in rapidly growing tissues: ornithine decarboxylase activity in regenerating rat liver, chick embryo, and various tumors. Proc Natl Acad Sci U S A. 1968;60:1420–7.CrossRefPubMedPubMedCentral

12.

Marton LJ, Pegg AE. Polyamines as targets for therapeutic intervention. Annu Rev Pharmacol Toxicol. 1995;35:55–91.CrossRefPubMed

13.

Paz EA, Garcia-Huidobro J, Ignatenkos NA. Polyamines in cancer. Adv Clin Chem. 2011;54:45–70.CrossRefPubMed

14.

Pegg AE, Feith DJ, Fong LY, Coleman CS, O'Brien TG, Shantz LM. Transgenic mouse models for studies of the role of polyamines in normal, hypertrophic and neoplastic growth. Biochem Soc Trans. 2003;31:356–60.CrossRefPubMed

15.

George K, Iacobucci A, Uitto J, O'Brien TG. Identification of an X-linked locus modifying mouse skin tumor susceptibility. Mol Carcinog. 2005;44:212–8.CrossRefPubMed

16.

Moshier JA, Dosescu J, Skunca M, Luk GD. Transformation of NIH/3T3 cells by ornithine decarboxylase overexpression. Cancer Res. 1993;53:2618–22.PubMed

17.

Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci U S A. 1993;90:7804–8.CrossRefPubMedPubMedCentral

18.

Packham G, Cleveland JL. The role of ornithine decarboxylase in c-Myc-induced apoptosis. Curr Top Microbiol Immunol. 1995;194:283–90.PubMed

19.

Meyskens Jr FL, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res. 1999;5:945–51.PubMed

20.

Kendra KL, Katzenellenbogen BS. An evaluation of the involvement of polyamines in modulating MCF-7 human breast cancer cell proliferation and progesterone receptor levels by estrogen and antiestrogen. J Steroid Biochem. 1987;28:123–8.CrossRefPubMed

21.

Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther. 2005;12:217–27.CrossRefPubMed

22.

Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004;22:326–30.CrossRefPubMed

23.

Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci. 2001;114:4557–65.PubMed

24.

Deshmukh SK, Srivastava SK, Bhardwaj A, Singh AP, Tyagi N, Marimuthu S, et al. Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation. Oncotarget. 2015;6:11231–41.CrossRefPubMedPubMedCentral

25.

Srivastava SK, Bhardwaj A, Arora S, Tyagi N, Singh AP, Carter JE, et al. Interleukin-8 is a key mediator of FKBP51-induced melanoma growth, angiogenesis and metastasis. Br J Cancer. 2015;112:1772–81.CrossRefPubMedPubMedCentral

26.

Landau G, Bercovich Z, Park MH, Kahana C. The role of polyamines in supporting growth of mammalian cells is mediated through their requirement for translation initiation and elongation. J Biol Chem. 2010;285:12474–81.CrossRefPubMedPubMedCentral

27.

Sutton D, Kim S, Shuai X, Leskov K, Marques JT, Williams BR, et al. Efficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. Int J Nanomedicine. 2006;1:155–62.CrossRefPubMedPubMedCentral

28.

Tyagi N, Bhardwaj A, Singh AP, McClellan S, Carter JE, Singh S. p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-kappaB pathway. Oncotarget. 2014;5:8778–89.CrossRefPubMedPubMedCentral

29.

Fuessel S, Herrmann J, Ning S, Kotzsch M, Kraemer K, Schmidt U, et al. Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Lett. 2006;232:243–54.CrossRefPubMed

30.

Du Q, Zhang Y, Tian XX, Li Y, Fang WG. MAGE-D1 inhibits proliferation, migration and invasion of human breast cancer cells. Oncol Rep. 2009;22:659–65.PubMed

31.

Zhang H, Zhang R, Liang P. Differential screening of differential display cDNA products by reverse northern. Methods Mol Biol. 1997;85:87–93.PubMed

32.

Hayes CS, DeFeo K, Lan L, Paul B, Sell C, Gilmour SK. Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells. Oncogene. 2006;25:1543–53.CrossRefPubMed

33.

Hibshoosh H, Johnson M, Weinstein IB. Effects of overexpression of ornithine decarboxylase (ODC) on growth control and oncogene-induced cell transformation. Oncogene. 1991;6:739–43.PubMed

34.

Feith DJ, Bol DK, Carboni JM, Lynch MJ, Sass-Kuhn S, Shoop PL, et al. Induction of ornithine decarboxylase activity is a necessary step for mitogen-activated protein kinase kinase-induced skin tumorigenesis. Cancer Res. 2005;65:572–8.PubMed

35.

Xu CX, Yan YF, Yang YP, Liu B, Xin JX, Chen SM, et al. Downregulation of ornithine decarboxylase by pcDNA-ODCr inhibits gastric cancer cell growth in vitro. Mol Biol Rep. 2011;38:949–55.CrossRefPubMed

36.

Chi W, Song X, Jiang C, Liu X, Li W, Wang X. Lentiviral vector-mediated downregulation of ornithine decarboxylase inhibits tumor cell growth in vitro and in vivo. Tumour Biol. 2006;27:243–51.CrossRefPubMed

37.

Mook OR, Baas F, de Wissel MB, Fluiter K. Evaluation of locked nucleic acid–modified small interfering RNA in vitro and in vivo. Mol Cancer Therap. 2007;6:833–43.CrossRef

38.

Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucl Acids Res. 2005;33:439–47.CrossRefPubMedPubMedCentral

39.

Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry. 2003;42:7967–75.CrossRefPubMed

40.

Pelofy S, Teissié J, Golzio M, Chabot S. Chemically modified oligonucleotide–increased stability negatively correlates with its efficacy despite efficient electrotransfer. J Membr Biol. 2012;245:1–7.CrossRef

41.

Lamberton JS, Christian AT. Varying the nucleic acid composition of siRNA molecules dramatically varies the duration and degree of gene silencing. Mol Biotechnol. 2003;24:111–20.CrossRefPubMed

42.

Nowak M, Wyszko E, Fedoruk-Wyszomirska A, Pospieszny H, Barciszewska MZ, Barciszewski J. A new and efficient method for inhibition of RNA viruses by DNA interference. FEBS J. 2009;276:4372–80.CrossRefPubMed

43.

Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004;305:1437–41.CrossRefPubMed

44.

Song J-J, Smith SK, Hannon GJ, Joshua-Tor L. Crystal structure of argonaute and its implications for RISC slicer activity. Science. 2004;305:1434–7.CrossRefPubMed

45.

Robb GB, Rana TM. RNA helicase A interacts with RISC in human cells and functions in RISC loading. Mol Cell. 2007;26:523–37.CrossRefPubMed

46.

Lee CG, Hurwitz J. A new RNA helicase isolated from HeLa cells that catalytically translocates in the 3' to 5' direction. J Biol Chem. 1992;267:4398–407.PubMed

47.

Zhang B, Liu XX, Zhang Y, Jiang CY, Teng QS, Hu HY, et al. Adenovirus-mediated expression of both antisense ODC and AdoMetDC inhibited colorectal cancer cell growth in vitro. Acta Pharmacol Sin. 2006;27:353–9.CrossRefPubMed

48.

Forshell TP, Rimpi S, Nilsson JA. Chemoprevention of B-cell lymphomas by inhibition of the Myc target spermidine synthase. Cancer Prev Res. 2010;3:140–7.CrossRef

49.

Luo J, Li YN, Wang F, Zhang WM, Geng X. S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer. Int J Biol Sci. 2010;6:784–95.CrossRefPubMedPubMedCentral

50.

Thomas T, Thomas TJ. Polyamine metabolism and cancer. J Cell Mol Med. 2003;7:113–26.CrossRefPubMed

51.

Bjorge JD, Pang AS, Funnell M, Chen KY, Diaz R, Magliocco AM, et al. Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line. Plos One. 2011;6:e19309. 19310.11371/journal.pone.0019309.CrossRefPubMedPubMedCentral

52.

Kunze D, Wuttig D, Fuessel S, Kraemer K, Kotzsch M, Meye A, et al. Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells. Anticancer Res. 2008;28:2259–63.PubMed

53.

Tian H, Liu X, Zhang B, Sun Q, Sun D. Adenovirus-mediated expression of both antisense ornithine decarboxylase and s-adenosylmethionine decarboxylase inhibits lung cancer cell growth. Acta Biochim Biophys Sin. 2007;39:423–30.CrossRefPubMed

54.

Song X, Tian H, Liu XX, Zhang B, Li WJ, Xu J. Ornithine decarboxylase and S-adenosylmethionine decarboxylase bi-antisense virus inhibit growth and invasion of esophageal cancer cell line Eca109. Ai Zheng (Chinese J Cancer). 2008;27:1144–9. Article in Chinese.

55.

G Landau, A Ran, Z Bercovich, E Feldmesser, S Horn-Saban, E Korkotian, J Jacob-Hirsch, G Rechavi, D Ron, C Kahana. Expression profiling and biochemical analysis suggest stress response as a potential mechanism inhibiting proliferation of polyamine depleted cells. Journal of Biological Chemistry. 2012; In Press:doi: 10.1074/jbc.M1112.381335.

56.

Yuan Q, Ray RM, Johnson LR. Polyamine depletion prevents camptothecin-induced apoptosis by inhibiting the release of cytochromec. Am J Physiol - Cell Physiol. 2002;282:C1290–7.CrossRefPubMed

57.

Xie S-Q, Li Q, Zhang Y-H, Wang J-H, Mei Z-H, Zhao J, et al. NPC-16, a novel naphthalimide–polyamine conjugate, induced apoptosis and autophagy in human hepatoma HepG2 cells and Bel-7402 cells. Apoptosis. 2011;16:27–34.CrossRefPubMed

58.

Zou T, Rao JN, Liu L, Xiao L, Cui Y-H, Jiang Z, et al. Polyamines inhibit the assembly of stress granules in normal intestinal epithelial cells regulating apoptosis. Am J Physiol - Cell Physiol. 2012;303:C102–11.CrossRefPubMedPubMedCentral

59.

Tsujinaka S, Soda K, Kano Y, Konishi F. Spermine accelerates hypoxia-initiated cancer cell migration. Int J Oncol. 2011;38:305–12.PubMed

60.

Kubota S, Kiyosawa H, Nomura Y, Yamada T, Seyama Y. Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion. J Natl Cancer Inst. 1997;89:567–71.CrossRefPubMed

61.

Matters GL, Manni A, Bond JS. Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells. Clin Exp Metastasis. 2005;22:331–9.CrossRefPubMed

62.

Zou T, Rao JN, Liu L, Marasa BS, Keledjian KM, Zhang AH, et al. Polyamine depletion induces nucleophosmin modulating stability and transcriptional activity of p53 in intestinal epithelial cells. Am J Physiol Cell Physiol. 2005;289:C686–696.CrossRefPubMed

63.

Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A. 1998;95:4997–5002.CrossRefPubMedPubMedCentral

Titel: Targeting polyamine biosynthetic pathway through RNAi causes the abrogation of MCF 7 breast cancer cell line
Publikationsdatum: 16.08.2015
Erschienen in: Tumor Biology / Ausgabe 1/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3912-2

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Targeting polyamine biosynthetic pathway through RNAi causes the abrogation of MCF 7 breast cancer cell line

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Upregulation of KPNβ1 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis

GPRC5A overexpression predicted advanced biological behaviors and poor prognosis in patients with gastric cancer

Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models

DNA methylation and detection of cervical cancer and precancerous lesions using molecular methods

Contribution of resident and recruited macrophages to the photodynamic intervention of colorectal tumor microenvironment

H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie